Posts
Spero Therapeutics is one of the strangest situations I’ve ever come across in biotech
Spero (currently trading at $3) is this tiny biotech firm with a pretty cool drug called tebipenem. It’s an oral carbapenem antibiotic for gnarly urinary tract infections. Anyways, everyone's holding their breath for June 18th as that’s when the FDA’s gonna make their ruling on tebipenem. Unlike most small companies, …
AI Bubble seems popping
All the big tech giants have started to go IPO alongside most of the deals are done through special purpose vehicle keeping the risk off the balancesheet. Japan and Korea index rallied just because of AI demand. Alphabet recent 80B sell of stock is too unprecedented. Microsoft tightening the belt …
S&P will NOT be changing their inclusion rules for MegaCap IPOs like SpaceX
[S&P Dow Jones Indices Consultation on Treatment of MegaCap Companies - Results - Jun 4, 2026](https://press.spglobal.com/2026-06-04-S-P-Dow-Jones-Indices-Consultation-on-Treatment-of-MegaCap-Companies-Results) There has been a lot of doomerism regarding the SpaceX IPO and how SP500 is changing their rules, causing people to go so far as to sell off their portfolio to avoid investing in …
SpaceX will be a very good Investment
There's the SpaceX is overpriced post. I'm adding one for discussion for those of you that think it's a good investment. Standard disclaimer - this is not financial advice and I have no special knowledge. This is just my opinion. Here's why I'm buying in to the IPO. 1. This …
Could SAP ever reclaim its position as Europe’s biggest company by market cap?
It’s been beaten down by the Saaspocalypse. Does the stock price have room to grow to its previous valuations or has the market permanently rerated enterprise software? It’s deeply embedded in the operations of many of the world’s largest companies. Replacing SAP isn’t something most enterprises can do overnight, which …
$LULU reports Q1 earnings
Q1 Results: Beat EPS, Beat Revenue Expectations 🔹 EPS: $1.69, beat consensus by $0.01 (consensus was $1.68) 🔹 Revenue: $2.47B, up 4.3% YoY, beat $2.43B consensus 🔹 Comparable Sales: +1% YoY (or -2% on a constant dollar basis) Americas: -5% YoY (-6% constant currency) International: +13% YoY (+8% constant currency) …
Sleeping on Nikkei 225
SoftBank just surpassed Toyota as #1 market cap in Japan. \#2 is KIOXIA a Bain/Toshiba semiconductor giant. Materials like Tokyo electron mooning too. I think PAYPAY (PAYP) is undervalued on Nasdaq. It's owned by SoftBank. It has a leading market share in Japan's payment market. 10b market cap only right …
Thoughts on Potential for SpaceX IPO Day 1 Pop - May be Enough IPO liquidity to actually minimize or prevent a pop
Putting the straight valuation issues of SpaceX aside - of which there are many - this post is oriented towards those that might be looking to participate in the IPO and sell on Day 1. That is, capitalize on any IPO Day 1 IPO pop. The main issue I see …
Do early investors in SpaceX need it's stock price to increase after IPO?
We all know the story about SpaceX's IPO, change of rules for including it as early as possible in indexes and the theory on how it's all being engineered to transfer wealth from pension funds to early investors in SpaceX. That's a thesis I personally find reasonable and I'm already …
I've been trading stocks for a month now and there is one fundamental thing I still don't understand.
Why did everyone agree to buy stocks in a company that does well and sell stocks in a company that does poorly? It seems that the entire market is running on this arbitrary agreement meanwhile theoretically the performance of a company shouldn't affect the stock price and if let's say …